Protein-misfolding diseases and chaperone-based therapeutic approaches

被引:287
作者
Chaudhuri, TK [1 ]
Paul, S [1 ]
机构
[1] Indian Inst Technol, Dept Biochem Engn & Biotechnol, New Delhi 110016, India
关键词
chaperone-based therapeutic approaches; chemical and pharmacological chaperones; molecular chaperones; protein conformational diseases; protein misfolding and aggregation;
D O I
10.1111/j.1742-4658.2006.05181.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A large number of neurodegenerative diseases in humans result from protein misfolding and aggregation. Protein misfolding is believed to be the primary cause of Alzheimer's disease, Parkinson's disease, Huntington's disease, Creutzfeldt-Jakob disease, cystic fibrosis, Gaucher's disease and many other degenerative and neurodegenerative disorders. Cellular molecular chaperones, which are ubiquitous, stress-induced proteins, and newly Found chemical and pharmacological chaperones have been found to be effective in preventing misfolding of different disease-causing proteins, essentially reducing the severity of several neurodegenerative disorders and many other protein-misfolding diseases. In this review, we discuss the probable mechanisms of several protein-misfolding diseases in humans, as well as therapeutic approaches for countering them. The role of molecular, chemical and pharmacological chaperones in suppressing the effect of protein misfolding-induced consequences in humans is explained in detail. Functional aspects of the different types of chaperones suggest their uses as potential therapeutic agents against different types of degenerative diseases, including neurodegenerative disorders.
引用
收藏
页码:1331 / 1349
页数:19
相关论文
共 148 条
  • [91] Recent advances in the genetics and pathogenesis of Parkinson disease
    Mouradian, MM
    [J]. NEUROLOGY, 2002, 58 (02) : 179 - 185
  • [92] Protein misfolding, amyloid formation, and neurodegeneration: A critical role for molecular chaperones?
    Muchowskil, PJ
    [J]. NEURON, 2002, 35 (01) : 9 - 12
  • [93] DE-NOVO EXPANSION OF A (CAG)(N) REPEAT IN SPORADIC HUNTINGTONS-DISEASE
    MYERS, RH
    MACDONALD, ME
    KOROSHETZ, WJ
    DUYAO, MP
    AMBROSE, CM
    TAYLOR, SAM
    BARNES, G
    SRINIDHI, J
    LIN, CS
    WHALEY, WL
    LAZZARINI, AM
    SCHWARZ, M
    WOLFF, G
    BIRD, ED
    VONSATTEL, JPG
    GUSELLA, JF
    [J]. NATURE GENETICS, 1993, 5 (02) : 168 - 173
  • [94] Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations
    Nikolova, PV
    Wong, KB
    DeDecker, B
    Henckel, J
    Fersht, AR
    [J]. EMBO JOURNAL, 2000, 19 (03) : 370 - 378
  • [95] THE SECRETED FORM OF THE ALZHEIMERS AMYLOID PRECURSOR PROTEIN WITH THE KUNITZ DOMAIN IS PROTEASE NEXIN-II
    OLTERSDORF, T
    FRITZ, LC
    SCHENK, DB
    LIEBERBURG, I
    JOHNSONWOOD, KL
    BEATTIE, EC
    WARD, PJ
    BLACHER, RW
    DOVEY, HF
    SINHA, S
    [J]. NATURE, 1989, 341 (6238) : 144 - 147
  • [96] The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity
    Ostrerova-Golts, N
    Petrucelli, L
    Hardy, J
    Lee, JM
    Farer, M
    Wolozin, B
    [J]. JOURNAL OF NEUROSCIENCE, 2000, 20 (16) : 6048 - 6054
  • [97] Support for the prion hypothesis for inheritance of a phenotypic trait in yeast
    Patino, MM
    Liu, JJ
    Glover, JR
    Lindquist, S
    [J]. SCIENCE, 1996, 273 (5275) : 622 - 626
  • [98] Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3
    Paulson, HL
    Perez, MK
    Trottier, Y
    Trojanowski, JQ
    Subramony, SH
    Das, SS
    Vig, P
    Mandel, JL
    Fischbeck, KH
    Pittman, RN
    [J]. NEURON, 1997, 19 (02) : 333 - 344
  • [99] Amyloid fibrils - Mutations make enzyme polymerize
    Perutz, MF
    [J]. NATURE, 1997, 385 (6619) : 773 - &
  • [100] Therapeutic approaches to repair defects in ΔF508 CFTR folding and cellular targeting
    Powell, K
    Zeitlin, PL
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (11) : 1395 - 1408